Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Gastric Cancer Clinical Trials

A listing of Gastric Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (18) clinical trials

Patients are needed to participate in a clinical research study of S-1, Cisplatin, Oxaliplatin

The primary endpoint is Overall survival time (OS).Secondary is overall response rate (ORR), time to treatment failure (TTF),treatment to progression time (TTP)and the adverse reactions of the two groups (AE). Study design: This is a prospective randomized control study. Sample size: Sample size considerations were based on the survival end ...


A clinical trial seeking patients for a research study for the treatment of Cellular aspects of, Cytology, gastrointestinal endoscopy, Gastric Cancer, Cytological Techniques, Esophageal Cancer, Esophagogastroduodenoscopy

Esophageal cancer is a common malignancy with a very poor prognosis. The principal reason for its poor prognosis is that most tumors are asymptomatic and go undetected until they have spread beyond the esophageal wall and are unresectable. Significant reduction in esophageal cancer mortality will require successful strategies to diagnose ...

Phase N/A

A clinical research study of Ropidoxuridine

PRIMARY OBJECTIVES: I. To conduct a phase I dose escalation trial, to determine the safety and the maximum tolerated dose (MTD), of oral (po) IPdR (ropidoxuridine) given daily for 28 consecutive days with concurrent intensity-modulated radiation therapy (IMRT) in patients with advanced gastrointestinal cancers treated with palliative radiation. SECONDARY OBJECTIVES: ...


A Phase 2 clinical study for patients with Gastric Cancer

After curative resection, patients with stage IIIB-IV (M0) gastric cancer were given chemotherapy as follows: S-1 orally at 80 mg/m2 divided in two daily doses for 14 days and oxaliplatin at 130 mg/m2 intravenously over 2 h every 21 days as one cycle. S1 was administered for 16 cycles (12 ...


A Phase 2 clinical study for patients with Thyroid Adenoma, Testicular Non-Seminomatous Germ Cell Tumor, Malignant Odontogenic Neoplasm, Primary Peritoneal High Grade Serous Adenocarcinoma, Bladder Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Gastric Squamous Cell Carcinoma, Transitional cell carcinoma, Urethral Adenocarcinoma, Mucinous Adenocarcinoma, Nasal Cavity Adenocarcinoma, Paranasal Sinus Adenocarcinoma, Chordoma, Appendix Mucinous Adenocarcinoma, Anal Canal Neuroendocrine Carcinoma, Lung Carcinoid Tumor, Metaplastic Breast Carcinoma, Adrenocortical carcinoma, Mucinous cystadenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Major Salivary Gland Carcinoma, Extrahepatic Bile Duct Carcinoma, Adenoid Cystic Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Nasopharyngeal Papillary Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ureter Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Placental site trophoblastic tumor, Vulvar Adenocarcinoma, Parathyroid Adenoma, Ovarian Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Rare Diseases, Paraganglioma, Pheochromocytoma, Endometrial Transitional Cell Carcinoma, Seminoma, Undifferentiated Gastric Carcinoma, Vaginal Adenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Acinar Cell Carcinoma, Pseudomyxoma Peritonei, Mesodermal mixed tumor, Islet cell carcinoma, Serous cystadenocarcinoma, Minimally Invasive Lung Adenocarcinoma, Fallopian Tube Adenocarcinoma, Ureter Adenocarcinoma, Nasopharyngeal Cancer, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Spindle Cell Neoplasm, Colorectal Squamous Cell Carcinoma, Endometrioid carcinoma, Cervical Adenocarcinoma, Malignant Testicular Sex Cord-Stromal Tumor, Esophageal Undifferentiated Carcinoma, Paranasal Sinus Cancer, Placental Choriocarcinoma, Pituitary Adenoma, Aggressive fibromatosis, Fibromyxoid Tumor, Teratoma With Malignant Transformation, Vulvar Carcinoma, Ovarian Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Penis, Urethral Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Cholangiocarcinoma, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Nasopharyngeal Undifferentiated Carcinoma, Giant cell carcinoma, Dermoid Cyst, Gastric Neuroendocrine Carcinoma, Tracheal Carcinoma, Oral Cavity Carcinoma, Nerve Sheath Tumors, Lung Sarcomatoid Carcinoma, Nasal Cavity Carcinoma, Neoplasms, Unknown Primary, Anal Canal Undifferentiated Carcinoma, gastrointestinal stromal tumor, Oropharyngeal Undifferentiated Carcinoma

PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. SECONDARY OBJECTIVES: I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free ...


A clinical trial seeking patients for a research study of CRS+HIPEC

Peritoneal metastases in gastric cancer are considered to indicate terminal disease due to poor prognosis because systemic chemotherapy is unlikely to accumulate in peritoneal nodules in cytotoxic concentrations. Cytoreductive surgery (CRS) along with hyperthermic intraperitoneal chemotherapy (HIPEC) has been suggested to improve survival in select patients with limited peritoneal spread, ...


Patients are needed to participate in a clinical research study of paclitaxel, everolimus, ibrutinib, cetuximab, docetaxel

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in selected advanced gastrointestinal and genitourinary tumors.


A clinical trial to evaluate treatments for patients with Advanced Gastric Cancer

The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.


Patients are needed to participate in a clinical research study for the treatment of Colorectal Cancer, head and neck cancer, bladder cancer, Carcinoma, Squamous Cell of Head and Neck, Renal Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Adenocarcinoma

This is a phase 1, open-label, multicenter, dose escalation study that will examine the safety profile of SGN-2FF given orally to patients with advanced solid tumors. The primary goal of the study is to identify the maximum tolerated dose (MTD), or optimal biological dose (OBD) that does not exceed the ...


Patients are needed to participate in a clinical research study of Gastric Cancer, Gastroesophageal Junction Adenocarcinoma to evaluate Paclitaxel

The study will compare the efficacy and safety of treatment with pembrolizumab (MK-3475) versus paclitaxel in Asian, programmed death-ligand 1 (PD-L1) positive participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination chemotherapy containing a platinum and a fluoropyrimidine agent. The primary study ...